The HIV-1 protease as a therapeutic target for AIDS.

HIV produces a small , dimeric aspartyl protease which specifically cleaves the polyprotein precursors encoding the structural proteins and enzymes of the virus. This proteolytic activity is absolutely required for the production of mature, infectious virions and is therefore an attractive target for therapeutic intervention. This review summarizes the strategies and multidisciplinary efforts that have been applied to date to the identification of specific inhibitors of this critical viral enzyme. These inhibitors include rationally designed peptide substrate analogs, compounds conceived from tertiary structure information on the enzyme and natural products. Future directions in the discovery and development of HIV-1 protease inhibitors are also discussed.

[1]  W. Schramm,et al.  HIV-1 reproduction is inhibited by peptides derived frm the N- and C-termini of HIV-1 protease. , 1991, Biochemical and biophysical research communications.

[2]  A. Tomasselli,et al.  Zinc inhibition of renin and the protease from human immunodeficiency virus type 1. , 1991, Biochemistry.

[3]  M. Minnich,et al.  Purification and biochemical characterization of recombinant simian immunodeficiency virus protease and comparison to human immunodeficiency virus type 1 protease. , 1991, Biochemistry.

[4]  T. Meek,et al.  Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. , 1991, Biochemistry.

[5]  R. Heinrikson,et al.  Dissociative inhibition of dimeric enzymes. Kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide. , 1991, The Journal of biological chemistry.

[6]  C. Hutchison,et al.  Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. , 1991, The Journal of biological chemistry.

[7]  K. Hui,et al.  A rational approach in the search for potent inhibitors against HIV proteinase , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  W. Howe,et al.  Inhibitors of the protease from human immunodeficiency virus: design and modeling of a compound containing a dihydroxyethylene isostere insert with high binding affinity and effective antiviral activity. , 1991, Journal of medicinal chemistry.

[9]  J. Craig,et al.  Effects of a Specific Inhibitor of HIV Proteinase (Ro 31-8959) on Virus Maturation in a Chronically Infected Promonocytic Cell Line (U1) , 1991 .

[10]  A Wlodawer,et al.  Structural and evolutionary relationships between retroviral and eucaryotic aspartic proteinases. , 1991, Biochemistry.

[11]  S. Redshaw,et al.  The inhibitory activity of a peptide derivative against the growth of simian immunodeficiency virus in C8166 cells. , 1991, Biochemical and biophysical research communications.

[12]  S. Vasavanonda,et al.  Potent HIV-1 protease inhibitors with antiviral activities in vitro. , 1991, Biochemical and biophysical research communications.

[13]  J. Louis,et al.  The effect of salt on the Michaelis Menten constant of the HIV‐1 protease correlates with the Hofmeister series , 1991, FEBS letters.

[14]  J. Louis,et al.  Purification of HIV‐1 wild‐type protease and characterization of proteolytically inactive HIV‐1 protease mutants by pepstatin A affinity chromatography , 1991, FEBS letters.

[15]  W. M. Sanders,et al.  L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor. , 1991, Journal of medicinal chemistry.

[16]  N. Roberts,et al.  Assay of HIV-1 proteinase: a colorimetric method using small peptide substrates. , 1991, Analytical biochemistry.

[17]  G. Marshall,et al.  Effect of hydroxyl group configuration in hydroxyethylamine dipeptide isosteres on HIV protease inhibition. Evidence for multiple binding modes. , 1991, Journal of medicinal chemistry.

[18]  A. Siccardi,et al.  A high throughput assay for inhibitors of HIV‐1 protease Screening of microbial metabolites , 1991, FEBS letters.

[19]  A Wlodawer,et al.  Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor. , 1991, Biochemistry.

[20]  L. Babe,et al.  Inhibition of HIV protease activity by heterodimer formation. , 1991, Biochemistry.

[21]  J. Springer,et al.  Structure and function of retroviral proteases. , 1991, Annual review of biophysics and biophysical chemistry.

[22]  G. Marshall,et al.  A simple, continuous fluorometric assay for HIV protease. , 2009, International journal of peptide and protein research.

[23]  T. Copeland,et al.  An Approach to the Synthesis of HIV Protease Inhibitors , 1990 .

[24]  S. Foundling,et al.  Stability and activity of human immunodeficiency virus protease: comparison of the natural dimer with a homologous, single-chain tethered dimer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[25]  T. Block,et al.  Novel bacteriological assay for detection of potential antiviral agents , 1990, Antimicrobial Agents and Chemotherapy.

[26]  Y. Gluzman,et al.  beta-Galactosidase containing a human immunodeficiency virus protease cleavage site is cleaved and inactivated by human immunodeficiency virus protease. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A Wlodawer,et al.  X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T L Blundell,et al.  The 3-D structure of HIV-1 proteinase and the design of antiviral agents for the treatment of AIDS. , 1990, Trends in biochemical sciences.

[29]  R. Dixon,et al.  Characterization of an active single polypeptide form of the human immunodeficiency virus type 1 protease. , 1990, The Journal of biological chemistry.

[30]  S. Vasavanonda,et al.  Structure-based, C2 symmetric inhibitors of HIV protease. , 1990, Journal of medicinal chemistry.

[31]  B. Moss,et al.  An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[32]  I. Kuntz,et al.  Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[33]  V. Kostka,et al.  Hydrolysis of synthetic chromogenic substrates by HIV-1 and HIV-2 proteinases. , 1990, Biochemical and biophysical research communications.

[34]  R. Simmer,et al.  Affinity purification of HIV-1 and HIV-2 proteases from recombinant E. coli strains using pepstatin-agarose. , 1990, Biochemical and biophysical research communications.

[35]  D. Decamp,et al.  Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2. , 1990, The Journal of biological chemistry.

[36]  D. Norbeck,et al.  Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. , 1990, Science.

[37]  T. Meek,et al.  A radiometric assay for HIV-1 protease. , 1990, Analytical biochemistry.

[38]  V. Kostka,et al.  Sub‐site preferences of the aspartic proteinase from the human immunodeficiency virus, HIV‐1 , 1990, FEBS letters.

[39]  J. Louis,et al.  A solid phase assay for the protease of human immunodeficiency virus. , 1990, Analytical Biochemistry.

[40]  Y. Gluzman,et al.  Isolation of mutants of human immunodeficiency virus protease based on the toxicity of the enzyme in Escherichia coli. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[41]  D. Grobelny,et al.  Selective phosphinate transition-state analogue inhibitors of the protease of human immunodeficiency virus. , 1990, Biochemical and biophysical research communications.

[42]  I. Weber.  Comparison of the crystal structures and intersubunit interactions of human immunodeficiency and Rous sarcoma virus proteases. , 1990, The Journal of biological chemistry.

[43]  W. Farmerie,et al.  Sensitive, soluble chromogenic substrates for HIV-1 proteinase. , 1990, The Journal of biological chemistry.

[44]  G R Marshall,et al.  Hydroxyethylamine analogues of the p17/p24 substrate cleavage site are tight-binding inhibitors of HIV protease. , 1990, Journal of medicinal chemistry.

[45]  J. Elting,et al.  A fluorometric assay for HIV-protease activity using high-performance liquid chromatography. , 1990, Analytical biochemistry.

[46]  I B Duncan,et al.  Rational design of peptide-based HIV proteinase inhibitors. , 1990, Science.

[47]  T. Meek,et al.  Chromophoric peptide substrates for the spectrophotometric assay of HIV-1 protease. , 1990, Biochemical and biophysical research communications.

[48]  M. Manneberg,et al.  Identification of a human immunodeficiency virus-1 protease cleavage site within the 66,000 Dalton subunit of reverse transcriptase. , 1990, Biochemical and biophysical research communications.

[49]  C. Vlahos,et al.  Substitutions at the P2' site of gag p17-p24 affect cleavage efficiency by HIV-1 protease. , 1990, Biochemical and biophysical research communications.

[50]  F. H. Yin,et al.  High-level synthesis of recombinant HIV-1 protease and the recovery of active enzyme from inclusion bodies. , 1990, Gene.

[51]  D. Danley,et al.  Fluorescence‐based continuous assay for the aspartyl protease of human immunodeficiency virus‐1 , 1990, FEBS letters.

[52]  Thomas Schulze,et al.  In vitro inhibition of HIV‐1 proteinase by cerulenin , 1990, FEBS letters.

[53]  Gary T. Wang,et al.  Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. , 1990, Science.

[54]  B. Dunn,et al.  Viral proteinases: weakness in strength. , 1990, Biochimica et biophysica acta.

[55]  Tomi K. Sawyer,et al.  A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. , 1990, Disease markers.

[56]  A. Tomasselli,et al.  Substrate analogue inhibition and active site titration of purified recombinant HIV-1 protease. , 1990, Biochemistry.

[57]  Brian W. Metcalf,et al.  Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues , 1990, Nature.

[58]  Gary T. Wang,et al.  DESIGN AND SYNTHESIS OF NEW FLUOROGENIC HIV PROTEASE SUBSTRATES BASED ON RESONANCE ENERGY TRANSFER , 1990 .

[59]  D. Davies,et al.  The structure and function of the aspartic proteinases. , 1990 .

[60]  Brian W. Metcalf,et al.  Human immunodeficiency virus protease: A target for aids therapy , 1990 .

[61]  E. Wimmer,et al.  Proteolytic processing of polyproteins in the replication of RNA viruses. , 1989, Biochemistry.

[62]  C. Debouck,et al.  Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[63]  A Wlodawer,et al.  Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. , 1989, Science.

[64]  John P. Overington,et al.  X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes , 1989, Nature.

[65]  R. Dixon,et al.  Affinity purification of the HIV-1 protease. , 1989, Biochemical and biophysical research communications.

[66]  E. Jacobs,et al.  Assembly and release of HIV-1 precursor Pr55 gag virus-like particles from recombinant baculovirus-infected insect cells , 1989, Cell.

[67]  T. Copeland,et al.  Synthetic non-peptide inhibitors of HIV protease. , 1989, Biochemical and biophysical research communications.

[68]  J. Louis,et al.  Continuous spectrophotometric assay for retroviral proteases of HIV-1 and AMV. , 1989, Biochemical and biophysical research communications.

[69]  C. Debouck,et al.  Recombinant HIV-1 reverse transcriptase: purification, primary structure, and polymerase/ribonuclease H activities. , 1989, Archives of biochemistry and biophysics.

[70]  B. Dunn,et al.  Inhibition of the aspartic proteinase from HIV‐2 , 1989, FEBS letters.

[71]  M. Jaskólski,et al.  Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. , 1989, Science.

[72]  Marianne Manchester,et al.  Complete mutagenesis of the HIV-1 protease , 1989, Nature.

[73]  B. Ho,et al.  Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity , 1989, Journal of virology.

[74]  A. Fauci,et al.  Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. , 1989, Science.

[75]  S. Oroszlan,et al.  The preparation and biochemical characterization of intact capsids of equine infectious anemia virus. , 1989, Biochemical and biophysical research communications.

[76]  B. Dunn,et al.  Effective blocking of HIV‐1 proteinase activity by characteristic inhibitors of aspartic proteinases , 1989, FEBS letters.

[77]  D. Richman,et al.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.

[78]  C. Debouck,et al.  Peptide substrates and inhibitors of the HIV-1 protease. , 1989, Biochemical and biophysical research communications.

[79]  C. Debouck,et al.  Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[80]  A Wlodawer,et al.  Molecular modeling of the HIV-1 protease and its substrate binding site. , 1989, Science.

[81]  M. Navia,et al.  Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 , 1989, Nature.

[82]  R. Dixon,et al.  Human immunodeficiency virus protease. Bacterial expression and characterization of the purified aspartic protease. , 1989, The Journal of biological chemistry.

[83]  E. Wimmer,et al.  Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[84]  C. Hutchison,et al.  Mutational analysis of human immunodeficiency virus type 1 protease suggests functional homology with aspartic proteinases , 1989, Journal of virology.

[85]  C. Debouck,et al.  Characterization and autoprocessing of precursor and mature forms of human immunodeficiency virus type 1 (HIV 1) protease purified from Escherichia coli , 1989, Proteins.

[86]  P. Štrop,et al.  Synthetic peptides as substrates and inhibitors of human immune deficiency virus-1 protease. , 1988, The Journal of biological chemistry.

[87]  R. Gallo,et al.  Processing of the structural proteins of human immunodeficiency virus type 1 in the presence of monensin and cerulenin. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[88]  T. Copeland,et al.  Genetic locus, primary structure, and chemical synthesis of human immunodeficiency virus protease. , 1988, Gene analysis techniques.

[89]  D. Veber,et al.  HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. , 1988, Biochemical and biophysical research communications.

[90]  V. Turk,et al.  Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[91]  E. Lillehoj,et al.  Purification and structural characterization of the putative gag-pol protease of human immunodeficiency virus , 1988, Journal of virology.

[92]  T. Copeland,et al.  Molecular characterization of gag proteins from simian immunodeficiency virus (SIVMne) , 1988, Journal of virology.

[93]  S. Kent,et al.  Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV-1 protease , 1988, Cell.

[94]  L J Davis,et al.  Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[95]  P. Sharp,et al.  Rates and dates of divergence between AIDS virus nucleotide sequences. , 1988, Molecular biology and evolution.

[96]  D. Baltimore,et al.  Standardized and simplified nomenclature for proteins common to all retroviruses , 1988, Journal of virology.

[97]  H. Varmus,et al.  Characterization of ribosomal frameshifting in HIV-1 gag-pol expression , 1988, Nature.

[98]  W. Mcclements,et al.  Oligopeptides inhibit the ribonucleotide reductase of herpes simplex virus by causing subunit separation. , 1988, Virology.

[99]  C. Debouck,et al.  Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[100]  William R. Taylor,et al.  A structural model for the retroviral proteases , 1987, Nature.

[101]  W R Taylor,et al.  Sequence specificity of retroviral proteases. , 1987, Nature.

[102]  S. Thaisrivongs,et al.  Renin inhibitors. Design of angiotensinogen transition-state analogues containing novel. (2R,3R,4R,5S)-5-amino-3,4-dihydroxy-2-isopropyl-7-methyloctanoic acid. , 1987, Journal of medicinal chemistry.

[103]  C. Hutchison,et al.  Expression and processing of the AIDS virus reverse transcriptase in Escherichia coli. , 1987, Science.

[104]  K. Ikuta,et al.  Inhibition of cleavage of Moloney murine leukemia virus gag and env coded precursor polyproteins by cerulenin. , 1986, Virology.

[105]  I. Katoh,et al.  The effect of cerulenin on Moloney murine leukemia virus morphogenesis. , 1986, Virus research.

[106]  É. Cohen,et al.  Specific inhibition of herpesvirus ribonucleotide reductase by a nonapeptide derived from the carboxy terminus of subunit 2 , 1986, Nature.

[107]  H. Marsden,et al.  Specific inhibition of herpesvirus ribonucleotide reductase by synthetic peptides , 1986, Nature.

[108]  C. Harris,et al.  Human renin: a new class of inhibitors. , 1986, Biochemical and biophysical research communications.

[109]  T. Miyata,et al.  Retroviral protease-like sequence in the yeast transposon Ty 1 , 1985, Nature.

[110]  W. Kati,et al.  Difluorostatine- and difluorostatone-containing peptides as potent and specific renin inhibitors. , 1985, Journal of medicinal chemistry.

[111]  M. Gelb,et al.  Fluoro ketone inhibitors of hydrolytic enzymes. , 1985, Biochemistry.

[112]  L. Lasky,et al.  Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus , 1985, Nature.

[113]  K. Steimer,et al.  Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). , 1985, Science.

[114]  Olivier Danos,et al.  Nucleotide sequence of the AIDS virus, LAV , 1985, Cell.

[115]  Mark L. Pearson,et al.  Complete nucleotide sequence of the AIDS virus, HTLV-III , 1985, Nature.

[116]  P. Bartlett,et al.  PHOSPHINIC ACID DIPEPTIDE ANALOGS: POTENT, SLOW‐BINDING INHIBITORS OF ASPARTIC PEPTIDASES , 1984 .

[117]  M. Szelke,et al.  Potent new inhibitors of human renin , 1982, Nature.

[118]  J. Harley,et al.  Effects of inhibitors of lipid synthesis on the replication of Rous sarcoma virus. A specific effect of cerulenin on the processing of major non-glycosylated viral structural proteins. , 1978, Biochimica et biophysica acta.

[119]  M. James,et al.  Mechanism of acid protease catalysis based on the crystal structure of penicillopepsin , 1977, Nature.

[120]  G J Williams,et al.  The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1977, Journal of molecular biology.

[121]  R. Wolfenden,et al.  Transition state analog inhibitors and enzyme catalysis. , 1976, Annual review of biophysics and bioengineering.